Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant acinetobacter baumannii strains isolated from bacteremia patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Bozkurt Guzel, Cagla ^a   Savage, Paul B ^b   Akcali, Alper ^c   Ozbek Celik, Berna ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Brigham Young University   (United States)

^c ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CERAGENIN CSA 13; CIPROFLOXACIN; COLISTIN; TOBRAMYCIN; UNCLASSIFIED DRUG; CARBAPENEM DERIVATIVE; CERAGENIN CSA-13; STEROID;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATION; BROTH DILUTION; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CROSS INFECTION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ACINETOBACTER BAUMANNII; CARBAPENEMS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; STEROIDS;

EID: 84899500584     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/710273     Document Type: Article

References (32)

1. Doi Y.; Husain S.; Potoski B. A.; McCurry K. R.; Paterson D. L.; Extensively drug-resistant Acinetobacter baumannii. Emerging Infectious Diseases 2009 15 6 980 982 2-s2.0-67449096824 10.3201/eid1506.081006
2. Higgins P. G.; Dammhayn C.; Hackel M.; Seifert H.; Global spread of carbapenem-resistant Acinetobacter baumannii. The Journal of Antimicrobial Chemotherapy 2010 65 2 233 238 2-s2.0-77949538109 10.1093/jac/dkp428
3. Cisneros J. M.; Reyes M. J.; Pachón J.; Becerril B.; Caballero F. J.; García-Garmendía J. L.; Ortiz C.; Cobacho A. R.; Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clinical Infectious Diseases 1996 22 6 1026 1032 2-s2.0-0029747205 (Pubitemid 26260606)
4. Seifert H.; Strate A.; Pulverer G.; Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine 1995 74 6 340 349 2-s2.0-0028786886 10.1097/00005792- 199511000-00004
5. Llaca-Díaz J. M.; Mendoza-Olazarán S.; Camacho-Ortiz A.; Flores S.; Garza-González E.; One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey, Mexico. Chemotherapy 2012 58 6 475 481 10.1159/000346352
6. Garnacho-Montero J.; Amaya-Villar R.; Multiresistant Acinetobacter baumannii infections: epidemiology and management. Current Opinion in Infectious Diseases 2010 23 4 332 339 2-s2.0-77954888053 10.1097/QCO.0b013e32833ae38b
7. Maragakis L. L.; Perl T. M.; Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical Infectious Diseases 2008 46 8 1254 1263 2-s2.0-42549108748 10.1086/529198 (Pubitemid 351589912)
8. Savage P. B.; Li C.; Taotafa U.; Ding B.; Guan Q.; Antibacterial properties of cationic steroid antibiotics. FEMS Microbiology Letters 2002 217 1 1 7 2-s2.0-0037137245 10.1016/S0378-1097(02)01036-4 (Pubitemid 35356536)
9. Hadley E. B.; Hancock R. E. W.; Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Current Topics in Medicinal Chemistry 2010 10 18 1872 1881 2-s2.0-78649922290
10. Lai X.-Z.; Feng Y.; Pollard J.; Chin J. N.; Rybak M. J.; Bucki R.; Epand R. F.; Epand R. M.; Savage P. B.; Ceragenins: cholic acid-based mimics of antimicrobial peptides. Accounts of Chemical Research 2008 41 10 1233 1240 2-s2.0-56249128811 10.1021/ar700270t
11. Chin J. N.; Rybak M. J.; Cheung C. M.; Savage P. B.; Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2007 51 4 1268 1273 2-s2.0-34247140867 10.1128/AAC.01325-06 (Pubitemid 46586804)
12. Chin J. N.; Jones R. N.; Sader H. S.; Savage P. B.; Rybak M. J.; Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. Journal of Antimicrobial Chemotherapy 2008 61 2 365 370 2-s2.0-38349170070 10.1093/jac/dkm457
13. Bozkurt-Guzel C.; Savage P. B.; Gerceker A. A.; In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy 2012 57 6 505 510 2-s2.0-84856203441 10.1159/000335588
14. Leszczyska K.; Namiot A.; Fein D. E.; Wen Q.; Namiot Z.; Savage P. B.; Diamond S.; Janmey P. A.; Bucki R.; Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiology 2009 9, article 187 2-s2.0-70349630154 10.1186/1471-2180-9-187
15. Isogai E.; Isogai H.; Takahashi K.; Okumura K.; Savage P. B.; Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria. Oral Microbiology and Immunology 2009 24 2 170 172 2-s2.0-60349129570 10.1111/j.1399-302X.2008.00464.x
16. Howell M. D.; Streib J. E.; Kim B. E.; Lesley L. J.; Dunlap A. P.; Geng D.; Feng Y.; Savage P. B.; Leung D. Y. M.; Ceragenins: a class of antiviral compounds to treat orthopox infections. Journal of Investigative Dermatology 2009 129 11 2668 2675 2-s2.0-70350074755 10.1038/jid.2009.120
17. Lara D.; Feng Y.; Bader J.; Savage P. B.; Maldonado R. A.; Anti-trypanosomatid activity of ceragenins. Journal of Parasitology 2010 96 3 638 642 2-s2.0-77953827385 10.1645/GE-2329.1
18. Saha S.; Savage P. B.; Bal M.; Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens. Journal of Applied Microbiology 2008 105 3 822 828 2-s2.0-49849083969 10.1111/j.1365-2672.2008.03820.x
19. Yahav D.; Farbman L.; Leibovici L.; Paul M.; Colistin: new lessons on an old antibiotic. Clinical Microbiology and Infection 2012 18 1 18 29 2-s2.0-83655164078 10.1111/j.1469-0691.2011.03734.x
20. Guan Q.; Li C.; Schmidt E. J.; Boswell J. S.; Walsh J. P.; Allman G. W.; Savage P. B.; Preparation and characterization of cholic acid-derived antimicrobial agents with controlled stabilities. Organic Letters 2000 2 18 2837 2840 2-s2.0-0034618315
21. Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Seventh Edition 2006 Wayne, Pa, USA CLSI Approved Standard M7-A7
22. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing: Twenty second Informational Supplement 2012 Wayne, Pa, USA CLSI M100-S22
23. National Committee for Clinical Laboratory Standards, Methods for Determining Bactericidal Activity of Antimicrobial Agents-Approved Guideline 1999 Wayne, Pa, USA NCCLS M26-A
24. Pillai S. K.; Moellering R. C. Jr.; Eliopoulos G. M.; Lorian V.; Antimicrobial combinations. Antibiotics in Laboratory Medicine 2005 Philadelphia, Pa, USA Lippincott Williams & Wilkins 365 440
25. Odds F. C.; Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy 2003 52 1, article 1 2-s2.0-0038601510
26. Epand R. F.; Pollard J. E.; Wright J. O.; Savage P. B.; Epand R. M.; Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrobial Agents and Chemotherapy 2010 54 9 3708 3713 2-s2.0-77956132155 10.1128/AAC.00380-10
27. Pogue J. M.; Mann T.; Barber K. E.; Kaye K. S.; Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Review of Anti-infective Therapy 2013 11 4 383 393 10.1586/eri.13.14
28. Carmeli Y.; Akova M.; Cornaglia G.; Daikos G. L.; Garau J.; Harbarth S.; Rossolini G. M.; Souli M.; Giamarellou H.; Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clinical Microbiology and Infection 2010 16 2 102 111 2-s2.0-74549155155 10.1111/j.1469-0691.2009.03115.x
29. Cai Y.; Chai D.; Wang R.; Liang B.; Bai N.; Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. Journal of Antimicrobial Chemotherapy 2012 67 7 1607 1615 10.1093/jac/dks084
30. Giannouli M.; Cuccurullo S.; Crivaro V.; di Popolo A.; Bernardo M.; Tomasone F.; Amato G.; Brisse S.; Triassi M.; Utili R.; Zarrilli R.; Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone. Journal of Clinical Microbiology 2010 48 4 1223 1230 2-s2.0-77950471423 10.1128/JCM.02263-09
31. Ergin A.; Hascelik G.; Eser O. K.; Molecular characterization of oxacillinases and genotyping of invasive Acinetobacter baumannii isolates using repetitive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010. Scandinavian Journal of Infectious Diseases 2013 45 1 26 31 10.3109/00365548.2012.708782
32. Jones R. N.; Pfaller M. A.; Marshall S. A.; Hollis R. J.; Wilke W. W.; Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood. Stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagnostic Microbiology and Infectious Disease 1997 29 3 187 192 2-s2.0-0030668767 10.1016/S0732-8893(97)81808-1 (Pubitemid 27519527)